

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Peter J. Pommerville)	
)	Art Unit: 1623
Serial No.: Not yet assigned)	
)	Examiner: Kathleen Kahler Fonda
Filed: Herewith)	
)	
For: Method for Preventing, Reducing, and)	
Treating Radiation Cystitis Using)	
Hyaluronic Acid)	

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO-1449, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of each cited item is enclosed unless stated otherwise hereinbelow.

Pursuant to 37 C.F.R. §1.98(d), inasmuch as this application relies on prior application Serial No. 09/830,063 filed July 30, 2001 for an earlier filing date under 35 U.S.C. § 120, no copy of any patent, publication or other information previously cited by or submitted to the Office in such prior application is being provided herewith.


I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Label No. EV 334684157 US in an envelope addressed to: Commissioner for Patents, Mailstop Patent Applications, P.O. Box 1450, Alexandria, VA 22313-1450, on November 10 2003.



Janina A. Malone, Reg. No. 47,768

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'J. Malone', written in a cursive style.

Janina A. Malone
Reg. No. 47,768

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 02811-0122 (42368-294223)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO <h1 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <p style="text-align: center;">(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	Not yet assigned
				Filing Date	herewith
				First Named Inventor	Peter J. Pommerville
				Group Art Unit	1623
				Examiner Name	Kathleen Kahler Fonda
				Attorney Docket Number	02811-0122 (42368-294223)

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Not yet assigned
		Filing Date	Herewith
		First Named Inventor	Peter J. Pommerville
		Group Art Unit	1623
		Examiner Name	Kathleen Kahler Fonda
Sheet 2 of 2	Attorney Docket Number	02811-0122 (42368-294223)	

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	6	DOWNEY, JOE et al., "Relative Efficacy of Various Exogenous Glycosaminoglycans in Providing a Bladder Surface Permeability Barrier", Journal of Urology, 1997, pp. 128, vol. 157, issue 4 Suppl.	
	7	LIGUORI, VINCENZO et al., "Double-Blind, Randomized Clinical Study Comparing Hyaluronic Acid Cream to Placebo in Patients Treated With Radiotherapy", Radiotherapy and Oncology, 1997, pp. 155-161, vol. 42, issue 2.	
	8	NICKEL, J. CURTIS et al., "The Bladder Mucus (Glycosaminoglycan) Layer in Interstitial Cystitis", The Journal of Urology, April 1993, pp.716-718, vol. 149.	
	9	OKEN, MARTIN M. et al., "Toxicity and Response Criteria of the Eastern Cooperative Oncology Group", Am. J. Clin. Oncol., 1982, pp. 649-655, vol. 5.	
	10	O'LEARY, MICHAEL P. et al., "The Interstitial Cystitis Symptom Index", Proceedings of the American Urological Association, May 1996, pp. 439A, vol. 155 supplement.	
	11	PORRU, DANIELE et al, "Results of Treatment of Refractory Interstitial Cystitis with Intravesical Hyaluronic Acid", Urologia Internationalis, 1997, pp. 26-29, vol. 59, issue 1.	
	12	STROHMAIER, W.L., "Therapie der Interstitiellen Bzw. Radiogenen Zystitis mit D Glukosamin", Helv. Chir. ACTA, 1989, pp. 323-325, vol. 56.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.